Replimune (REPL) Operating Expenses (2017 - 2026)

Replimune (REPL) has 10 years of Operating Expenses data on file, last reported at $73.3 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 7.55% year-over-year to $73.3 million; the trailing twelve-month figure through Mar 2026 stood at $319.9 million (up 22.28% YoY), and the FY2026 full-year result was $319.9 million, up 22.28% from the prior year.
• Operating Expenses climbed to $73.3 million in Q1 2026, from $71.9 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $90.4 million in Q2 2025 to a low of $32.0 million in Q1 2022.
• A 5-year average of $60.3 million and a median of $58.8 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses surged 65.67% in 2023 and retreated 7.7% in 2024, its largest moves.
• Tracing REPL's Operating Expenses over 5 years: stood at $41.6 million in 2022, then jumped by 35.82% to $56.5 million in 2023, then grew by 16.77% to $66.0 million in 2024, then climbed by 8.86% to $71.9 million in 2025, then gained by 2.05% to $73.3 million in 2026.
• Business Quant data shows REPL's Operating Expenses at $73.3 million in Q1 2026, $71.9 million in Q4 2025, and $84.3 million in Q3 2025.